EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$6.04
+1.60%Margins
Gross margin
100.0%
EBITDA margin
-1003.6%
EBIT margin
-1018.9%
Net margin
-946.7%
FCF margin
-746.5%
-34.1%
Return on equity
-31.4%
Return on assets
-35.7%
Return on invested capital
0.03x
Asset turnover
-$74.2M
Cash from operations
$5.53
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026